A monoclonal antibody (RT97) against neurofilament protein specifically and exclusively labelled a subpopulation of rat dorsal root ganglion (DRG) neurones. For seven ganglia (L4 and T13) studied quantitatively the frequency distribution histograms of the size of labelled cells could be fitted by a single normal distribution whose parameters were extremely close to those of the normally distributed large light cell population in that ganglion. On this basis and on the basis of a statistical analysis of the results it was suggested that this antibody can be used as a much needed specific label for the large light population of neurones in rat DRGs. The small dark neurone population was not labelled by this antibody. In one ganglion the subjective analysis of whether each neurone was labelled or not was directly compared with microdensitometric measurements of reaction product intensity. This analysis supported the above conclusion, and furthermore no subdivisions of the labelled population were apparent on the basis of neuronal size plotted against intensity of the reaction product. Other neuronal cell bodies strongly labelled by this antibody were found in association with small unlabelled neurones not only in DRGs, but also in the trigeminal ganglion, the vagal ganglia, and the mesencephalic V nucleus, all of which are made up of primary afferent neurones and all of which are completely or partially derived from the neural crest. Sympathetic and central nervous system neuronal cell bodies were unlabelled or occasionally very lightly labelled although immunoreactive fibres abound in the central nervous system.
The monoclonal antibody UJ13A was raised following immunization of mice with human foetal brain and subsequent somatic cell hyridization of spleen cells with the mouse myeloma cell line P3-X63-AG8-653. The antibody is of the IgG1 subclass and has been shown by indirect immunofluorescence studies on normal foetal, paediatric and adult tissues to selectively bind to most tissues of neuroectodermal origin. Many tumours of neural origin also express the UJ13A antigen and the reagent can be used to distinguish primary intracranial neural tumours from secondary carcinomas and lymphomas. UJ13A is also useful as one of a panel of reagents employed for the identification of metastatic spread of neuroblastoma cells to bone marrow and cerebrospinal fluid. Knowledge of the full spectrum of normal and malignant tissues binding UJ13A suggests that the antibody may have a role in the radioimmunolocalization of neuronal tumours such as neuroblastoma.
Conventional antibodies have long been used in an attempt to produce specific neural markers. Such markers would be invaluable for studying the structural organization and development of the nervous system. Unfortunately, they have not been found to discriminate satisfactorily between neuronal subpopulations. Recent developments of the hybridoma technique, however, promise to provide monoclonal antibodies of adequate specificity. Such antibodies have already generated and shown to be capable of distinguishing between individual neurones of the leech nervous system. We report here two monoclonal antibodies which, although generated against human T cells, react exclusively with Purkinje cells in the vertebrate central nervous system (CNS). This new specificity arose out of a fortuitous observation made during examination of the lymphocyte infiltration of human cerebellar tumours with the monoclonal antibody, UCHT1. Although widely used as a T-cell marker, its reaction with neural tissue has not hitherto been described. To our knowledge, this is the first description of a monoclonal antibody which recognises discrete neuronal population in the vertebrate brain.
This paper reviews the diagnostic role of monoclonal antibody immunohistochemistry in a series of 189 brain tumour biopsies and 22 cases of neoplastic meningitis. The diagnostic monoclonal antibody panel, which includes markers for glial, neural, epithelial and lymphoid differentiation antigens, was used to test a wide variety of cerebral and spinal tumours by indirect immunofluorescence and immunoperoxidase techniques on unfixed frozen sections. Gliomas, meningiomas, schwannomas, medulloblastomas, choroid plexus tumours, cerebral lymphomas and metastatic carcinomas could all be reliably differentiated by means of their characteristic antigenics profiles, as defined by their patterns of reactivity with the antibody panel. Confident diagnosis was possible even in very poorly differentiated tumours and in biopsies distorted by surgical squeeze artefact, where paucity of morphological clues made diagnosis by conventional histological methods difficult or impossible. It was estimated that use of the antibody panel was responsible for, or made a significant contribution towards the final diagnosis in approximately 20% of cases. The monoclonal reagents were also found to be of great value in the detection and characterisation of neoplastic cells in CSF specimens from patients with malignant meningitis. Malignant cells were detected in 73% of cases and characterised in 16% of cases by routine cytological techniques. Employing monoclonal immunocytology however, these figures were improved to 95% and 95% respectively. Our findings suggest that patients with neoplastic meningitis can be spared prolonged investigation and inappropriate management by the early detection and characterisation of malignant cells in CSF using panels of monoclonal antibodies.
The direct and indirect effects of histamine on the cutaneous microvasculature were measured by laser Doppler velocimetry. Histamine (6.51 x 10(-4) M) was injected intradermally into the forearms of eight healthy subjects following treatment with a topically applied local anaesthetic cream (EMLA) or equivalent placebo. The blood flow at the injection site (0 cm) and at 1 and 2 cm proximally was measured by laser Doppler velocimetry over 80 minutes. Analysis of the changes in magnitude of the hyperaemic responses with time showed no difference at the 0 and 1 cm sites, but a marked reduction was found at the 2 cm site following EMLA treatment (p less than 0.05). At all three sites the decay of the histamine-induced hyperaemia was faster following EMLA treatment than with placebo (p less than 0.04). The experiments showed that the indirect effect of histamine on the cutaneous microvasculature in the peripheral flare around the injection site was greatly diminished by prior application of EMLA cream and this supports the neurogenic hypothesis: pre-treatment with EMLA cream did not affect the development of hyperaemia and oedema at the site of histamine injection where the mediator acts directly on the cutaneous microvasculature.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.